BRPI0511754A - uso de um composto ou sais ou solvatos do mesmo - Google Patents

uso de um composto ou sais ou solvatos do mesmo

Info

Publication number
BRPI0511754A
BRPI0511754A BRPI0511754-2A BRPI0511754A BRPI0511754A BR PI0511754 A BRPI0511754 A BR PI0511754A BR PI0511754 A BRPI0511754 A BR PI0511754A BR PI0511754 A BRPI0511754 A BR PI0511754A
Authority
BR
Brazil
Prior art keywords
solvates
salts
compound
relates
quinazolinamines
Prior art date
Application number
BRPI0511754-2A
Other languages
English (en)
Inventor
Mark S Berger
Iman El-Hariry
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
David Rusnak
Neil L Spector
Original Assignee
Smithkline Beechman Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beechman Cork Ltd filed Critical Smithkline Beechman Cork Ltd
Publication of BRPI0511754A publication Critical patent/BRPI0511754A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

USO DE UM COMPOSTO OU SAIS OU SOLVATOS DO MESMO A presente invenção diz respeito a um método de tratar o câncer em um mamífero pela administração de 4-quinazolinaminas e composições farmacêuticas que as contenham. Em particular, o método diz respeito a um método de tratar cânceres que são mediados pelas tirosina quinases EGER e/ou erbB2 pela administração de N-{3-cloro-4-¢(3-fluorobenzil)óxi!fenil}-6- ¢5 -({¢2-(metanossulfonil)etil!amino}metil)-2-furil!-4-quinazolinamina e sais e solvatos do mesmo.
BRPI0511754-2A 2004-06-03 2005-06-01 uso de um composto ou sais ou solvatos do mesmo BRPI0511754A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57682504P 2004-06-03 2004-06-03
US60679004P 2004-09-02 2004-09-02
PCT/US2005/019053 WO2005120504A2 (en) 2004-06-03 2005-06-01 Cancer treatment method

Publications (1)

Publication Number Publication Date
BRPI0511754A true BRPI0511754A (pt) 2008-01-02

Family

ID=35503647

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511754-2A BRPI0511754A (pt) 2004-06-03 2005-06-01 uso de um composto ou sais ou solvatos do mesmo

Country Status (14)

Country Link
US (1) US20100063074A1 (pt)
EP (1) EP1768963A4 (pt)
JP (1) JP2008501690A (pt)
KR (1) KR20070030240A (pt)
AU (1) AU2005251722B2 (pt)
BR (1) BRPI0511754A (pt)
CA (1) CA2569132A1 (pt)
IL (1) IL179359A0 (pt)
MA (1) MA28691B1 (pt)
MX (1) MXPA06013635A (pt)
NO (1) NO20066077L (pt)
NZ (1) NZ551622A (pt)
RU (1) RU2006142420A (pt)
WO (1) WO2005120504A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009001814A (es) * 2006-08-22 2009-03-02 Concert Pharmaceuticals Inc Derivados de 4-aminoquinazolina y metodos de uso de los mismos.
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US20100197915A1 (en) * 2008-08-06 2010-08-05 Leonid Metsger Lapatinib intermediates
EP2158913A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
TR201808450T4 (tr) 2012-03-23 2018-07-23 Array Biopharma Inc Beyin kanserinin tedavisinde kullanılmaya yönelik amorf katı dispersiyon.
JP7328151B2 (ja) 2017-04-28 2023-08-16 シージェン インコーポレイテッド Ｈｅｒ２陽性がんの処置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CN1211382C (zh) * 2000-06-30 2005-07-20 葛兰素集团有限公司 喹唑啉二甲苯磺酸盐化合物
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
JP2004002210A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
CN100352441C (zh) * 2002-04-16 2007-12-05 阿斯特拉曾尼卡有限公司 用于治疗肿瘤的zd6126和zd1839的联合药物
WO2004000094A2 (en) * 2002-06-19 2003-12-31 Smithkline Beecham Corporation Predictive markers in cancer therapy
CN100522955C (zh) * 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
JP2004144680A (ja) * 2002-10-25 2004-05-20 Nanko Kyo 細胞増殖を制御する物質のスクリーニング方法、及びＳｐ１分子等をヌクレオリン（ｎｕｃｌｅｏｌｉｎ）分子から解離させる物質のスクリーニング方法

Also Published As

Publication number Publication date
WO2005120504A3 (en) 2006-02-23
WO2005120504A2 (en) 2005-12-22
MA28691B1 (fr) 2007-06-01
US20100063074A1 (en) 2010-03-11
AU2005251722A1 (en) 2005-12-22
JP2008501690A (ja) 2008-01-24
EP1768963A4 (en) 2009-06-10
IL179359A0 (en) 2007-03-08
NO20066077L (no) 2007-01-31
EP1768963A2 (en) 2007-04-04
KR20070030240A (ko) 2007-03-15
NZ551622A (en) 2010-01-29
RU2006142420A (ru) 2008-07-20
CA2569132A1 (en) 2005-12-22
MXPA06013635A (es) 2007-02-28
AU2005251722B2 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
BRPI0511754A (pt) uso de um composto ou sais ou solvatos do mesmo
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
CY1118846T1 (el) Τριαζολοπυριδαζινες ως ρυθμιστες της κινασης τυροσινης
MY169272A (en) Her2 antibody composition
BRPI0518794A2 (pt) composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
BRPI0516968A (pt) composto, composição, e, método de tratamento de distúrbio hiperproliferativo
CY1116191T1 (el) Παραγωγα πυριδαζινονης
CY1115925T1 (el) Παραγωγα πυριδαζινονης
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
CY1116015T1 (el) Καινοφανεις ενωσεις και μεθοδοι για θεραπεια
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
ATE554087T1 (de) Neue kinaseinhibitoren
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DE602006007037D1 (de) Pyrrolotriazin-kinasehemmer
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
HUP0302544A2 (hu) Receptor tirozinkináz-gátlókat és vérérképződés-gátlókat alkalmazó kombinált terápia
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
BR0211926A (pt) agentes para realçar a resposta imune
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
EA200801430A1 (ru) Производные триазола

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.